Aggressive Lymphomas
News
Shorter R-CHOP regimen noninferior in certain DLBCL patients
SAN DIEGO—A shortened regimen of four cycles of rituximab (R) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy...
News
Update shows durable responses in rel/ref DLBCL
SAN DIEGO—An updated analysis of the JULIET trial showed that tisagenlecleucel produced a high rate of durable responses in adults with relapsed...
Video
JULIET: CAR T cells go the distance in r/r DLBCL
SAN DIEGO – Median overall survival among patients with complete responses to CAR-T cell therapy in the JULIET trial has not been reached.
Conference Coverage
JULIET: CAR T cells keep trucking against DLBCL
SAN DIEGO – Median overall survival for patients with complete responses to CAR T-cell therapy was not reached through 19 months of follow-up.
News
New PCNSL guidelines emphasize importance of patient fitness
New guidelines on the diagnosis and management of patients with primary central nervous system lymphoma (PCNSL) emphasize prompt diagnosis,...
Conference Coverage
FLYER: Four cycles of R-CHOP as good as six in low-risk DLBCL
SAN DIEGO – Survival outcomes were nearly identical and adverse events were lower with four versus six cycles of R-CHOP in patients with favorable...
Video
FLYER: R-CHOP 4 safer, as effective for low-risk DLBCL patients under 60
SAN DIEGO – Progression-free, event-free, and overall survival were comparable with that of patients assigned to six cycles of therapy.
Guidelines
CNS lymphoma guidelines stress patient fitness, not age, in choosing treatment
Patients should be diagnosed fast, treated as aggressively as organ health permits, and in clinical trials if possible.
Conference Coverage
Your guide to ASH 2018: Abstracts to watch
News
FDA approves biosimilar rituximab for NHL
The U.S.
From the Journals
Cortactin expression aids in CLL-MCL differential
Cortactin, a cytoskeleton-remodeling adapter protein, is expressed on most CLL cells, but not similar-appearing MCL cells.